mouse vegf elisa kit picokine  (Boster Bio)


Bioz Verified Symbol Boster Bio is a verified supplier
Bioz Manufacturer Symbol Boster Bio manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Boster Bio mouse vegf elisa kit picokine
    Activation of calcineurin/NFAT/HIF-1α signaling induces a Piezo1-mediated increase in <t>VEGF-A</t> expression in BMDMs. (A) RT-PCR analysis of HIF-1α mRNA levels in BMDMs 6 h after Yoda1 treatment (n = 3 independent experiments, Tukey test). (B) Western blot analysis of HIF-1α accumulation in BMDMs 24 h after Yoda1 treatment. Blots are representative of three independent experiments. (C) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with echinomycin (Ecn) for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (D) <t>ELISA</t> analysis of VEGF-A expression in BMDMs pretreated with Ecn for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (E) Western blot analysis of NFATC1 and NFATC3 in BMDMs treated with Yoda1 for 24 h. (F) Western blot analysis of HIF-1α in BMDMs pretreated with CsA or FK506 for 30 min before 24-h Yoda1 (5 μM) treatment. Blots are representative of three independent experiments. (G) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with CsA or FK506 for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (H) ELISA analysis of VEGF-A expression in BMDMs pretreated with CsA or FK506 for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (I) Western blot analysis of NFATC1 and NFATC3 in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 24-h Yoda1 (5 μM) treatment. Blots are representative of three independent experiments. (J) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (K) ELISA analysis of VEGF-A expression in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). Data are shown as mean ± SD. * P
    Mouse Vegf Elisa Kit Picokine, supplied by Boster Bio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse vegf elisa kit picokine/product/Boster Bio
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mouse vegf elisa kit picokine - by Bioz Stars, 2022-07
    94/100 stars

    Images

    1) Product Images from "Piezo1-mediated mechanosensation in bone marrow macrophages promotes vascular niche regeneration after irradiation injury"

    Article Title: Piezo1-mediated mechanosensation in bone marrow macrophages promotes vascular niche regeneration after irradiation injury

    Journal: Theranostics

    doi: 10.7150/thno.64963

    Activation of calcineurin/NFAT/HIF-1α signaling induces a Piezo1-mediated increase in VEGF-A expression in BMDMs. (A) RT-PCR analysis of HIF-1α mRNA levels in BMDMs 6 h after Yoda1 treatment (n = 3 independent experiments, Tukey test). (B) Western blot analysis of HIF-1α accumulation in BMDMs 24 h after Yoda1 treatment. Blots are representative of three independent experiments. (C) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with echinomycin (Ecn) for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (D) ELISA analysis of VEGF-A expression in BMDMs pretreated with Ecn for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (E) Western blot analysis of NFATC1 and NFATC3 in BMDMs treated with Yoda1 for 24 h. (F) Western blot analysis of HIF-1α in BMDMs pretreated with CsA or FK506 for 30 min before 24-h Yoda1 (5 μM) treatment. Blots are representative of three independent experiments. (G) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with CsA or FK506 for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (H) ELISA analysis of VEGF-A expression in BMDMs pretreated with CsA or FK506 for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (I) Western blot analysis of NFATC1 and NFATC3 in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 24-h Yoda1 (5 μM) treatment. Blots are representative of three independent experiments. (J) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (K) ELISA analysis of VEGF-A expression in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). Data are shown as mean ± SD. * P
    Figure Legend Snippet: Activation of calcineurin/NFAT/HIF-1α signaling induces a Piezo1-mediated increase in VEGF-A expression in BMDMs. (A) RT-PCR analysis of HIF-1α mRNA levels in BMDMs 6 h after Yoda1 treatment (n = 3 independent experiments, Tukey test). (B) Western blot analysis of HIF-1α accumulation in BMDMs 24 h after Yoda1 treatment. Blots are representative of three independent experiments. (C) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with echinomycin (Ecn) for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (D) ELISA analysis of VEGF-A expression in BMDMs pretreated with Ecn for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (E) Western blot analysis of NFATC1 and NFATC3 in BMDMs treated with Yoda1 for 24 h. (F) Western blot analysis of HIF-1α in BMDMs pretreated with CsA or FK506 for 30 min before 24-h Yoda1 (5 μM) treatment. Blots are representative of three independent experiments. (G) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with CsA or FK506 for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (H) ELISA analysis of VEGF-A expression in BMDMs pretreated with CsA or FK506 for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (I) Western blot analysis of NFATC1 and NFATC3 in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 24-h Yoda1 (5 μM) treatment. Blots are representative of three independent experiments. (J) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (K) ELISA analysis of VEGF-A expression in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). Data are shown as mean ± SD. * P

    Techniques Used: Activation Assay, Expressing, Reverse Transcription Polymerase Chain Reaction, Western Blot, Enzyme-linked Immunosorbent Assay

    Residual BM-Mφs upregulate VEGF-A after irradiation. (A) Quantification of bone marrow VEGF-A levels by ELISA at indicated times after 5-Gy irradiation and treatment with PBS-lip or Mφs depletion by Clo-lip (n = 4-5 mice). * P
    Figure Legend Snippet: Residual BM-Mφs upregulate VEGF-A after irradiation. (A) Quantification of bone marrow VEGF-A levels by ELISA at indicated times after 5-Gy irradiation and treatment with PBS-lip or Mφs depletion by Clo-lip (n = 4-5 mice). * P

    Techniques Used: Irradiation, Enzyme-linked Immunosorbent Assay, Mouse Assay

    2) Product Images from "VEGF alleviates lower limb ischemia in diabetic mice by altering muscle fiber types"

    Article Title: VEGF alleviates lower limb ischemia in diabetic mice by altering muscle fiber types

    Journal: Experimental and Therapeutic Medicine

    doi: 10.3892/etm.2022.11176

    VEGF overexpression in gastrocnemius induces muscle fiber type switch in ischemic mice. (A) GFP marker levels 14 days after Ad-VEGF-GFP and Ad-GFP injection in skeletal muscle tissues were assessed by fluorescence microscopy. Scale bar=200 µm. (B) VEGF levels at 14 days as determined using ELISA. (C) Immunofluorescence staining of MHCIIa fibers (red) of ischemic gastrocnemius following treatment with Ad-VEGF-GFP or Ad-GFP. Scale Bars, 100 µm. (D) Citrate synthase activity in gastrocnemius. Data are presented as the mean ± standard deviation and are representative of 2 independent experiments. n=3 mice/group in each independent experiment. ** P
    Figure Legend Snippet: VEGF overexpression in gastrocnemius induces muscle fiber type switch in ischemic mice. (A) GFP marker levels 14 days after Ad-VEGF-GFP and Ad-GFP injection in skeletal muscle tissues were assessed by fluorescence microscopy. Scale bar=200 µm. (B) VEGF levels at 14 days as determined using ELISA. (C) Immunofluorescence staining of MHCIIa fibers (red) of ischemic gastrocnemius following treatment with Ad-VEGF-GFP or Ad-GFP. Scale Bars, 100 µm. (D) Citrate synthase activity in gastrocnemius. Data are presented as the mean ± standard deviation and are representative of 2 independent experiments. n=3 mice/group in each independent experiment. ** P

    Techniques Used: Over Expression, Mouse Assay, Marker, Injection, Fluorescence, Microscopy, Enzyme-linked Immunosorbent Assay, Immunofluorescence, Staining, Activity Assay, Standard Deviation

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Boster Bio mouse vegf elisa kit picokine
    Activation of calcineurin/NFAT/HIF-1α signaling induces a Piezo1-mediated increase in <t>VEGF-A</t> expression in BMDMs. (A) RT-PCR analysis of HIF-1α mRNA levels in BMDMs 6 h after Yoda1 treatment (n = 3 independent experiments, Tukey test). (B) Western blot analysis of HIF-1α accumulation in BMDMs 24 h after Yoda1 treatment. Blots are representative of three independent experiments. (C) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with echinomycin (Ecn) for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (D) <t>ELISA</t> analysis of VEGF-A expression in BMDMs pretreated with Ecn for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (E) Western blot analysis of NFATC1 and NFATC3 in BMDMs treated with Yoda1 for 24 h. (F) Western blot analysis of HIF-1α in BMDMs pretreated with CsA or FK506 for 30 min before 24-h Yoda1 (5 μM) treatment. Blots are representative of three independent experiments. (G) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with CsA or FK506 for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (H) ELISA analysis of VEGF-A expression in BMDMs pretreated with CsA or FK506 for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (I) Western blot analysis of NFATC1 and NFATC3 in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 24-h Yoda1 (5 μM) treatment. Blots are representative of three independent experiments. (J) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (K) ELISA analysis of VEGF-A expression in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). Data are shown as mean ± SD. * P
    Mouse Vegf Elisa Kit Picokine, supplied by Boster Bio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse vegf elisa kit picokine/product/Boster Bio
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mouse vegf elisa kit picokine - by Bioz Stars, 2022-07
    94/100 stars
      Buy from Supplier

    94
    Boster Bio vegf elisa kit
    ERK5 knockdown inhibits LLC tumor growth and increases tumor radiosensitivity. a – c Tumor growth was suppressed in LLC-bearing C57BL/6J mice treated with ERK5 knockdown combined with low-dose IR. When visible tumors were formed, local irradiation treatments (cumulative dose of 6 Gy) were fractionally administered on days 0, 2, and 4, and constructs expressing either Luc shRNA or ERK5 shRNA were injected into the tumor mass on days 1, 3, and 5. The tumor growth inhibitory effects of different treatments were compared ( a ). Tumor doubling time ( b ) and tumor delay time ( c ) are also shown. d – f Tumor growth was suppressed in LLC-bearing C57BL/6J mice treated with ERK5 knockdown combined with high-dose IR. When visible tumors were formed, local irradiation (total dose of 30 Gy) was fractionally administered on days 0, 2, 4, 6, 8, and 10, and a construct expressing either Luc shRNA or ERK5 shRNA was injected into the tumor mass on days 1, 3, and 5. The tumor growth inhibitory effects of different treatments were compared ( d ). Tumor doubling time ( e ) and tumor delay time ( f ) are also shown. g , h Blood vessel density within tumors was characterized by anti-CD31 immunostaining using an anti-mouse CD31 monoclonal antibody ( g ) and determined by the average number of vessels in 3 regions of the highest density at ×200 magnification in each section (the assay was repeated in 4 sections per mouse, and 3 mice were tested) ( h ). i Total protein was extracted from LLC tumors, and the intracellular <t>VEGF</t> level was detected via <t>ELISA</t> using 100 μg total protein per well. The data are presented as the mean ± SD; * p
    Vegf Elisa Kit, supplied by Boster Bio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vegf elisa kit/product/Boster Bio
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    vegf elisa kit - by Bioz Stars, 2022-07
    94/100 stars
      Buy from Supplier

    Image Search Results


    Activation of calcineurin/NFAT/HIF-1α signaling induces a Piezo1-mediated increase in VEGF-A expression in BMDMs. (A) RT-PCR analysis of HIF-1α mRNA levels in BMDMs 6 h after Yoda1 treatment (n = 3 independent experiments, Tukey test). (B) Western blot analysis of HIF-1α accumulation in BMDMs 24 h after Yoda1 treatment. Blots are representative of three independent experiments. (C) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with echinomycin (Ecn) for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (D) ELISA analysis of VEGF-A expression in BMDMs pretreated with Ecn for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (E) Western blot analysis of NFATC1 and NFATC3 in BMDMs treated with Yoda1 for 24 h. (F) Western blot analysis of HIF-1α in BMDMs pretreated with CsA or FK506 for 30 min before 24-h Yoda1 (5 μM) treatment. Blots are representative of three independent experiments. (G) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with CsA or FK506 for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (H) ELISA analysis of VEGF-A expression in BMDMs pretreated with CsA or FK506 for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (I) Western blot analysis of NFATC1 and NFATC3 in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 24-h Yoda1 (5 μM) treatment. Blots are representative of three independent experiments. (J) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (K) ELISA analysis of VEGF-A expression in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). Data are shown as mean ± SD. * P

    Journal: Theranostics

    Article Title: Piezo1-mediated mechanosensation in bone marrow macrophages promotes vascular niche regeneration after irradiation injury

    doi: 10.7150/thno.64963

    Figure Lengend Snippet: Activation of calcineurin/NFAT/HIF-1α signaling induces a Piezo1-mediated increase in VEGF-A expression in BMDMs. (A) RT-PCR analysis of HIF-1α mRNA levels in BMDMs 6 h after Yoda1 treatment (n = 3 independent experiments, Tukey test). (B) Western blot analysis of HIF-1α accumulation in BMDMs 24 h after Yoda1 treatment. Blots are representative of three independent experiments. (C) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with echinomycin (Ecn) for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (D) ELISA analysis of VEGF-A expression in BMDMs pretreated with Ecn for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (E) Western blot analysis of NFATC1 and NFATC3 in BMDMs treated with Yoda1 for 24 h. (F) Western blot analysis of HIF-1α in BMDMs pretreated with CsA or FK506 for 30 min before 24-h Yoda1 (5 μM) treatment. Blots are representative of three independent experiments. (G) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with CsA or FK506 for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (H) ELISA analysis of VEGF-A expression in BMDMs pretreated with CsA or FK506 for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (I) Western blot analysis of NFATC1 and NFATC3 in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 24-h Yoda1 (5 μM) treatment. Blots are representative of three independent experiments. (J) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (K) ELISA analysis of VEGF-A expression in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). Data are shown as mean ± SD. * P

    Article Snippet: Concentrations of VEGF-A were measured using the Mouse VEGF-A ELISA Kit (EK0541, Boster, China), according to the manufacturer's instructions.

    Techniques: Activation Assay, Expressing, Reverse Transcription Polymerase Chain Reaction, Western Blot, Enzyme-linked Immunosorbent Assay

    Residual BM-Mφs upregulate VEGF-A after irradiation. (A) Quantification of bone marrow VEGF-A levels by ELISA at indicated times after 5-Gy irradiation and treatment with PBS-lip or Mφs depletion by Clo-lip (n = 4-5 mice). * P

    Journal: Theranostics

    Article Title: Piezo1-mediated mechanosensation in bone marrow macrophages promotes vascular niche regeneration after irradiation injury

    doi: 10.7150/thno.64963

    Figure Lengend Snippet: Residual BM-Mφs upregulate VEGF-A after irradiation. (A) Quantification of bone marrow VEGF-A levels by ELISA at indicated times after 5-Gy irradiation and treatment with PBS-lip or Mφs depletion by Clo-lip (n = 4-5 mice). * P

    Article Snippet: Concentrations of VEGF-A were measured using the Mouse VEGF-A ELISA Kit (EK0541, Boster, China), according to the manufacturer's instructions.

    Techniques: Irradiation, Enzyme-linked Immunosorbent Assay, Mouse Assay

    VEGF overexpression in gastrocnemius induces muscle fiber type switch in ischemic mice. (A) GFP marker levels 14 days after Ad-VEGF-GFP and Ad-GFP injection in skeletal muscle tissues were assessed by fluorescence microscopy. Scale bar=200 µm. (B) VEGF levels at 14 days as determined using ELISA. (C) Immunofluorescence staining of MHCIIa fibers (red) of ischemic gastrocnemius following treatment with Ad-VEGF-GFP or Ad-GFP. Scale Bars, 100 µm. (D) Citrate synthase activity in gastrocnemius. Data are presented as the mean ± standard deviation and are representative of 2 independent experiments. n=3 mice/group in each independent experiment. ** P

    Journal: Experimental and Therapeutic Medicine

    Article Title: VEGF alleviates lower limb ischemia in diabetic mice by altering muscle fiber types

    doi: 10.3892/etm.2022.11176

    Figure Lengend Snippet: VEGF overexpression in gastrocnemius induces muscle fiber type switch in ischemic mice. (A) GFP marker levels 14 days after Ad-VEGF-GFP and Ad-GFP injection in skeletal muscle tissues were assessed by fluorescence microscopy. Scale bar=200 µm. (B) VEGF levels at 14 days as determined using ELISA. (C) Immunofluorescence staining of MHCIIa fibers (red) of ischemic gastrocnemius following treatment with Ad-VEGF-GFP or Ad-GFP. Scale Bars, 100 µm. (D) Citrate synthase activity in gastrocnemius. Data are presented as the mean ± standard deviation and are representative of 2 independent experiments. n=3 mice/group in each independent experiment. ** P

    Article Snippet: The supernatant was used to assay the concentration of VEGF (cat. no. EK0541; Boster Biological Technology) and enzyme activity of citric acid synthase (cat. no. MAK057; Sigma-Aldrich, Merck KGaA) according to manufacturer's protocols.

    Techniques: Over Expression, Mouse Assay, Marker, Injection, Fluorescence, Microscopy, Enzyme-linked Immunosorbent Assay, Immunofluorescence, Staining, Activity Assay, Standard Deviation

    Triptolide and VNP20009 Synergistically Inhibit the Tumour Angiogenisis by Suppressing the Production of VEGF. A) Immunohistochemistry of CD31 + cells and VEGF expression in melanoma tumours from mice receiving triptolide and/or VNP20009 (VNP) treatments on d 7 post infection. CD31 + cells are indicated by red arrows. Bars on VEGF sections represent 10 μm . B) The quantification of CD31 + microvessels in tumours. Two sections per tumour were determined and four tumours were harvested in each group. The number of the CD31 + cells was calculated. Mean ± S.D., n=8 . C) VEGF expression in melanoma tumours was examined by RT-PCR. D) ELISA assays were performed to determine VEGF concentration in tumours. Mean ± S.D., n=4 . E) The treatment schedule of the combination therapy of VNP and VEGF neutralizing antibody, and its effect on the growth of tumours. The VEGF neutralizing antibody (10 μg / tumour) or the IgG control antibody (10 μg / tumour) were injected directly into the tumours three times on d 7, 9 and 10. VNP was intraperitoneally injected on d 8 post tumour inoculation. Mean ± S.D., n=5 . F) The bacterial colonization in the tumours was determined on d 5 post VNP infection in the VEGF neutralization assay. Mean ± S.D., n=5 .

    Journal: Theranostics

    Article Title: Modulation of Salmonella Tumor-Colonization and Intratumoral Anti-angiogenesis by Triptolide and Its Mechanism

    doi: 10.7150/thno.18816

    Figure Lengend Snippet: Triptolide and VNP20009 Synergistically Inhibit the Tumour Angiogenisis by Suppressing the Production of VEGF. A) Immunohistochemistry of CD31 + cells and VEGF expression in melanoma tumours from mice receiving triptolide and/or VNP20009 (VNP) treatments on d 7 post infection. CD31 + cells are indicated by red arrows. Bars on VEGF sections represent 10 μm . B) The quantification of CD31 + microvessels in tumours. Two sections per tumour were determined and four tumours were harvested in each group. The number of the CD31 + cells was calculated. Mean ± S.D., n=8 . C) VEGF expression in melanoma tumours was examined by RT-PCR. D) ELISA assays were performed to determine VEGF concentration in tumours. Mean ± S.D., n=4 . E) The treatment schedule of the combination therapy of VNP and VEGF neutralizing antibody, and its effect on the growth of tumours. The VEGF neutralizing antibody (10 μg / tumour) or the IgG control antibody (10 μg / tumour) were injected directly into the tumours three times on d 7, 9 and 10. VNP was intraperitoneally injected on d 8 post tumour inoculation. Mean ± S.D., n=5 . F) The bacterial colonization in the tumours was determined on d 5 post VNP infection in the VEGF neutralization assay. Mean ± S.D., n=5 .

    Article Snippet: For ELISA, tissue homogenates were subjected to the ELISA procedure as described by using the mouse VEGF ELISA kit (Boster, Wuhan, China).

    Techniques: Immunohistochemistry, Expressing, Mouse Assay, Infection, Reverse Transcription Polymerase Chain Reaction, Enzyme-linked Immunosorbent Assay, Concentration Assay, Injection, Neutralization

    ERK5 knockdown inhibits LLC tumor growth and increases tumor radiosensitivity. a – c Tumor growth was suppressed in LLC-bearing C57BL/6J mice treated with ERK5 knockdown combined with low-dose IR. When visible tumors were formed, local irradiation treatments (cumulative dose of 6 Gy) were fractionally administered on days 0, 2, and 4, and constructs expressing either Luc shRNA or ERK5 shRNA were injected into the tumor mass on days 1, 3, and 5. The tumor growth inhibitory effects of different treatments were compared ( a ). Tumor doubling time ( b ) and tumor delay time ( c ) are also shown. d – f Tumor growth was suppressed in LLC-bearing C57BL/6J mice treated with ERK5 knockdown combined with high-dose IR. When visible tumors were formed, local irradiation (total dose of 30 Gy) was fractionally administered on days 0, 2, 4, 6, 8, and 10, and a construct expressing either Luc shRNA or ERK5 shRNA was injected into the tumor mass on days 1, 3, and 5. The tumor growth inhibitory effects of different treatments were compared ( d ). Tumor doubling time ( e ) and tumor delay time ( f ) are also shown. g , h Blood vessel density within tumors was characterized by anti-CD31 immunostaining using an anti-mouse CD31 monoclonal antibody ( g ) and determined by the average number of vessels in 3 regions of the highest density at ×200 magnification in each section (the assay was repeated in 4 sections per mouse, and 3 mice were tested) ( h ). i Total protein was extracted from LLC tumors, and the intracellular VEGF level was detected via ELISA using 100 μg total protein per well. The data are presented as the mean ± SD; * p

    Journal: Experimental & Molecular Medicine

    Article Title: Extracellular signal-regulated kinase 5 increases radioresistance of lung cancer cells by enhancing the DNA damage response

    doi: 10.1038/s12276-019-0209-3

    Figure Lengend Snippet: ERK5 knockdown inhibits LLC tumor growth and increases tumor radiosensitivity. a – c Tumor growth was suppressed in LLC-bearing C57BL/6J mice treated with ERK5 knockdown combined with low-dose IR. When visible tumors were formed, local irradiation treatments (cumulative dose of 6 Gy) were fractionally administered on days 0, 2, and 4, and constructs expressing either Luc shRNA or ERK5 shRNA were injected into the tumor mass on days 1, 3, and 5. The tumor growth inhibitory effects of different treatments were compared ( a ). Tumor doubling time ( b ) and tumor delay time ( c ) are also shown. d – f Tumor growth was suppressed in LLC-bearing C57BL/6J mice treated with ERK5 knockdown combined with high-dose IR. When visible tumors were formed, local irradiation (total dose of 30 Gy) was fractionally administered on days 0, 2, 4, 6, 8, and 10, and a construct expressing either Luc shRNA or ERK5 shRNA was injected into the tumor mass on days 1, 3, and 5. The tumor growth inhibitory effects of different treatments were compared ( d ). Tumor doubling time ( e ) and tumor delay time ( f ) are also shown. g , h Blood vessel density within tumors was characterized by anti-CD31 immunostaining using an anti-mouse CD31 monoclonal antibody ( g ) and determined by the average number of vessels in 3 regions of the highest density at ×200 magnification in each section (the assay was repeated in 4 sections per mouse, and 3 mice were tested) ( h ). i Total protein was extracted from LLC tumors, and the intracellular VEGF level was detected via ELISA using 100 μg total protein per well. The data are presented as the mean ± SD; * p

    Article Snippet: The ELISA for VEGF was performed by using a VEGF ELISA kit (Boster, Wuhan, China) according to the manufacturer’s instructions.

    Techniques: Mouse Assay, Irradiation, Construct, Expressing, shRNA, Injection, Immunostaining, Enzyme-linked Immunosorbent Assay